Evolent Health(US:EVH)2025-08-07 20:15markdown [Executive Summary](index=1&type=section&id=Executive%20Summary) Evolent Health exceeded Q2 EBITDA targets, raised full-year profitability outlook, and saw accelerating new business, driven by demand for specialty care solutions and progress with Auth Intelligence AI [Q2 2025 Performance Overview](index=1&type=section&id=Q2%202025%20Performance%20Overview) Evolent Health exceeded its Q2 EBITDA targets and raised its full-year profitability outlook, driven by a rapidly accelerating new business pipeline and robust demand for complex specialty care solutions. The company also noted progress with its Auth Intelligence AI and automation targets - **Evolent** exceeded **Q2 EBITDA targets** and raised the **full-year profitability outlook**[3](index=3&type=chunk) - The company anticipates exceeding **historical growth rates for 2026** due to a **rapidly accelerating new business pipeline**[3](index=3&type=chunk) - **Auth Intelligence**, one year after launch, is on track to achieve **near-term AI and automation targets by the end of 2025**, aspiring to become a market leader in clinical data exchange and AI[3](index=3&type=chunk) - **Robust demand** for Evolent's **complex specialty care solutions** is driven by **rising medical costs** impacting health plans[3](index=3&type=chunk) Financial Highlights (Q2 2025 vs Q2 2024) ($ in thousands) | Metric | Q2 2025 | Q2 2024 | Change | | :--------------------------------------- | :-------- | :-------- | :------- | | Revenue | $444,328 | $647,145 | -31.3% | | Net loss attributable to common shareholders | $(51,090) | $(6,383) | -700.4% | | Net loss margin | (11.5)% | (1.0)% | -10.5 pp | | Adjusted EBITDA | $37,547 | $51,950 | -27.7% | | Adjusted EBITDA Margin | 8.5% | 8.0% | +0.5 pp | Operational Highlights (Q2 2025 vs Q2 2024) | Metric | Q2 2025 | Q2 2024 | Change | | :----------------------------------- | :-------- | :-------- | :------- | | Performance Suite Lives on Platform | 6,490 | 6,901 | -5.9% | | Specialty Technology and Services Suite Lives on Platform | 77,019 | 71,701 | +7.4% | | Administrative Services Lives on Platform | 1,231 | 1,268 | -2.9% | | Cases | 13 | 15 | -13.3% | | Average Unique Members | 40,201 | 39,856 | +0.9% | Average PMPM Fees/Revenue per Case (Q2 2025 vs Q2 2024) ($) | Metric | Q2 2025 | Q2 2024 | Change | | :----------------------------------- | :-------- | :-------- | :------- | | Performance Suite | $13.76 | $22.30 | -38.3% | | Specialty Technology and Services Suite | $0.35 | $0.38 | -7.9% | | Administrative Services | $15.13 | $15.97 | -5.2% | | Cases | $2,969 | $2,849 | +4.2% | [CEO Commentary](index=1&type=section&id=CEO%20Commentary) Seth Blackley, Co-Founder and CEO, highlighted Evolent's strong Q2 performance, exceeding EBITDA targets and raising the full-year profitability outlook. He emphasized the accelerating new business pipeline, the company's critical role in improving healthcare quality and affordability, and confidence in achieving AI and automation targets with Auth Intelligence - **Evolent** exceeded **Q2 EBITDA targets** and raised the **full-year profitability outlook**[3](index=3&type=chunk) - The company expects to exceed historical growth rates for 2026 due to a rapidly accelerating new business pipeline[3](index=3&type=chunk) - Evolent's solutions aim to improve quality for members, reduce administrative burden for providers, and manage affordability for the system[3](index=3&type=chunk) - Confidence in achieving near-term AI and automation targets exiting 2025 with Auth Intelligence, aiming to become a leader in clinical data exchange and AI[3](index=3&type=chunk) [Financial Performance](index=1&type=section&id=Financial%20Performance) Evolent Health reported a significant GAAP net loss in Q2 2025, while adjusted results showed a decrease in Adjusted EBITDA despite margin improvement, alongside mixed operational metric trends [GAAP Reported Results](index=2&type=section&id=GAAP%20Reported%20Results) Evolent Health reported a net loss attributable to common shareholders of $(51.1) million for Q2 2025, a significant increase from $(6.4) million in Q2 2024, despite a decrease in revenue. Loss per share also increased substantially GAAP Financial Results (Q2 2025 vs Q2 2024) ($ in thousands) | Metric | Q2 2025 | Q2 2024 | Change | | :--------------------------------------- | :-------- | :-------- | :------- | | Revenue | $444,328 | $647,145 | -31.3% | | Cost of revenue | $343,943 | $540,302 | -36.3% | | Selling, general and administrative expenses | $75,209 | $69,185 | +8.7% | | Net loss attributable to common shareholders | $(51,090) | $(6,383) | -700.4% | | Net loss margin | (11.5)% | (1.0)% | -10.5 pp | | Loss per share (Basic and diluted) | $(0.44) | $(0.06) | -633.3% | - **Total cash and cash equivalents** were **$151.0 million** as of June 30, 2025[5](index=5&type=chunk) [Non-GAAP Adjusted Results](index=2&type=section&id=Non-GAAP%20Adjusted%20Results) Evolent Health's adjusted results for Q2 2025 show a decrease in Adjusted EBITDA and a shift from adjusted income to adjusted loss per common share compared to Q2 2024, despite an increase in Adjusted EBITDA margin Adjusted Financial Results (Q2 2025 vs Q2 2024) ($ in thousands) | Metric | Q2 2025 | Q2 2024 | Change | | :--------------------------------------- | :-------- | :-------- | :------- | | Adjusted cost of revenue | $342,893 | $539,095 | -36.4% | | Adjusted selling, general and administrative expenses | $63,888 | $56,100 | +13.9% | | Adjusted EBITDA | $37,547 | $51,950 | -27.7% | | Adjusted EBITDA margin | 8.5% | 8.0% | +0.5 pp | | Adjusted income (loss) attributable to common shareholders | $(11,013) | $21,065 | -152.3% | | Adjusted income (loss) per common share (Basic) | $(0.10) | $0.18 | -155.6% | [Key Operational Metrics](index=1&type=section&id=Key%20Operational%20Metrics) Evolent's operational metrics for Q2 2025 show mixed trends, with growth in Specialty Technology and Services Suite Lives on Platform and Cases revenue per case, but declines in Performance Suite and Administrative Services metrics Average Lives on Platform/Cases (Q2 2025 vs Q2 2024) | Metric | Q2 2025 | Q2 2024 | Change | | :----------------------------------- | :-------- | :-------- | :------- | | Performance Suite | 6,490 | 6,901 | -5.9% | | Specialty Technology and Services Suite | 77,019 | 71,701 | +7.4% | | Administrative Services | 1,231 | 1,268 | -2.9% | | Cases | 13 | 15 | -13.3% | | Average Unique Members | 40,201 | 39,856 | +0.9% | Average PMPM Fees/Revenue per Case (Q2 2025 vs Q2 2024) ($) | Metric | Q2 2025 | Q2 2024 | Change | | :----------------------------------- | :-------- | :-------- | :------- | | Performance Suite | $13.76 | $22.30 | -38.3% | | Specialty Technology and Services Suite | $0.35 | $0.38 | -7.9% | | Administrative Services | $15.13 | $15.97 | -5.2% | | Cases | $2,969 | $2,849 | +4.2% | [Business Developments](index=2&type=section&id=Business%20Developments) Evolent Health secured four new revenue agreements in Q2 2025, expanding existing partnerships with new states, lines of business, and specialty care solutions [New Revenue Agreements](index=2&type=section&id=New%20Revenue%20Agreements) Evolent announced four new revenue agreements in Q2 2025, bringing the year-to-date total to 11. These agreements include expansions with existing national and regional partners, adding new states, lines of business, and specialty care solutions like Oncology, Cardiology, Radiation Oncology, and Musculoskeletal services - **Evolent** announced **four new revenue agreements** in **Q2 2025**, bringing the year-to-date total to **11**[4](index=4&type=chunk) - An existing national partner is adding a new state in the mid-west for Oncology and Cardiology - An existing partner in the north-east will add cardiology, radiation oncology, and musculoskeletal solutions across multiple lines of business for more than 400,000 members - A regional partner in New England will add musculoskeletal and cardiology services across multiple lines of business - A national partner will add additional musculoskeletal services to a plan in the northeast[7](index=7&type=chunk) [Business Outlook and Guidance](index=3&type=section&id=Business%20Outlook%20and%20Guidance) Evolent Health provided Q3 2025 guidance and revised its full-year 2025 outlook, raising Adjusted EBITDA while adjusting revenue due to go-live timing, maintaining strong customer retention [Third Quarter 2025 Guidance](index=3&type=section&id=Third%20Quarter%202025%20Guidance) For the third quarter ending September 30, 2025, Evolent expects revenue to be in the range of $460 million to $480 million, and Adjusted EBITDA to be between $34 million and $42 million Third Quarter 2025 Guidance ($ in millions) | Metric | Range | | :------------- | :------------ | | Revenue | $460M - $480M | | Adjusted EBITDA | $34M - $42M | [Full Year 2025 Guidance](index=3&type=section&id=Full%20Year%202025%20Guidance) Evolent revised its full-year 2025 guidance, raising the Adjusted EBITDA outlook to $140 million to $165 million. The revenue outlook was adjusted to $1.85 billion to $1.88 billion, reflecting updated go-live timing for certain Performance Suite launches, while customer retention and pipeline activity remain strong Full Year 2025 Guidance ($ in millions/billions) | Metric | Range | | :------------- | :------------ | | Adjusted EBITDA | $140M - $165M (raised) | | Revenue | $1.85B - $1.88B (revised) | - The **revenue outlook revision** is due to **updated go-live timing** for certain Performance Suite launches[10](index=10&type=chunk) - The company continues to experience **strong customer retention** and **late-stage pipeline activity**[10](index=10&type=chunk) [Capitalized Software Development Outlook](index=3&type=section&id=Capitalized%20Software%20Development%20Outlook) Evolent reiterated its expectation to deploy approximately $35 million in cash for capitalized software development during 2025 - Expected **cash deployment** for **capitalized software development** in **2025**: approximately **$35 million**[11](index=11&type=chunk) [Company Information](index=3&type=section&id=Company%20Information) Evolent Health, Inc. specializes in improving healthcare outcomes for complex conditions, providing details on its Q2 2025 conference call and investor relations contact [About Evolent Health, Inc.](index=3&type=section&id=About%20Evolent%20Health,%20Inc.) Evolent specializes in improving health outcomes for individuals with complex conditions by providing solutions that make healthcare simpler and more affordable. The company serves a national base of leading payers and providers and is recognized as a top workplace in healthcare - **Evolent** specializes in **better health outcomes** for people with **complex conditions**[14](index=14&type=chunk) - Provides **proven solutions** that make **health care simpler and more affordable**[14](index=14&type=chunk) - Serves a **national base of leading payers and providers** and is consistently recognized as a **top place to work in health care**[14](index=14&type=chunk) [Web and Conference Call Information](index=3&type=section&id=Web%20and%20Conference%20Call%20Information) Evolent Health held a conference call on August 7, 2025, to discuss its financial performance. Details for accessing the live broadcast via the investor relations website and participating by telephone were provided, with an archive available for one week - **Conference call** held on **August 7, 2025**, at **5:00 p.m. Eastern Time**[13](index=13&type=chunk) - **Live broadcast** and accompanying materials available on the Company's **Investor Relations website** at http://ir.evolent.com[13](index=13&type=chunk) - **Telephone participation details** provided for domestic and international callers[13](index=13&type=chunk) [Contacts](index=3&type=section&id=Contacts) For investor relations inquiries, Evolent Health can be contacted via email at investorrelations@evolent.com - **Investor relations contact**: investorrelations@evolent.com[15](index=15&type=chunk) [Supplemental Information](index=5&type=section&id=Supplemental%20Information) This section provides definitions for Evolent Health's key operational metrics and explains the rationale and adjustments for its non-GAAP financial measures [Definitions of Key Operational Metrics](index=5&type=section&id=Definitions%20of%20Key%20Operational%20Metrics) This section defines key operational metrics used by Evolent, including Revenue Agreements, Lives on Platform (Performance Suite, Specialty Technology and Services Suite, Administrative Services), Cases, PMPM Fees, Revenue per Case, and Average Unique Members, explaining their calculation and relevance for evaluating unit economics and operational performance - **Revenue Agreements:** Include incremental revenue from new partner entities or additional sales to existing partners (services, geographic, line of business expansions, or conversion of Specialty Technology to Performance Suite contracts) Excludes renewals, membership growth within existing contracts, or transaction-related purchase agreements - **Lives on Platform:** Calculated by summing monthly members covered for specialty care services (Performance Suite, Specialty Technology and Services Suite) or administrative services (Administrative Services), divided by the number of months in the period - **Cases:** Sum of individuals receiving services through surgery management and advanced care planning programs in a given period - **Average PMPM Fee:** Revenue for a specific suite divided by its Lives on Platform for the period, divided by the number of months - **Revenue per Case:** Revenue for surgery management and advanced care planning programs divided by the number of cases - **Average Unique Members:** Sum of members covered by Performance Suite, Specialty Technology and Services Suite, and Administrative Services, with members crossing multiple solutions counted only once from the solution with maximum members[16](index=16&type=chunk)[17](index=17&type=chunk)[18](index=18&type=chunk)[19](index=19&type=chunk) - Management uses these measures to provide insight into the **unit economics of services** and **period-over-period operational performance**[20](index=20&type=chunk) [Non-GAAP Financial Measures Explanation](index=11&type=section&id=Non-GAAP%20Financial%20Measures%20Explanation) Evolent presents several non-GAAP financial measures, including Adjusted Cost of Revenue, Adjusted SG&A, Adjusted EBITDA, Adjusted EBITDA Margin, Adjusted Income (Loss) Attributable to Common Shareholders, and Adjusted EPS. These measures are used to provide investors with a clearer understanding of fundamental operational performance by excluding non-recurring or non-operational costs such as stock-based compensation, severance, transaction-related, and repositioning costs - **Non-GAAP financial measures** are presented as supplemental measures to help investors evaluate **fundamental operational performance**[28](index=28&type=chunk) - **Adjusted Cost of Revenue and Adjusted Selling, General and Administrative Expenses:** Exclude stock-based compensation, severance, transaction-related, and repositioning costs to facilitate understanding of long-term operational costs - **Adjusted EBITDA:** Excludes various non-operating and non-cash items from net loss attributable to common shareholders to focus on operational performance - **Adjusted EBITDA Margin:** Adjusted EBITDA divided by Revenue, useful for understanding operational performance compared to revenues over time - **Adjusted Income (Loss) Attributable to Common Shareholders and Adjusted Income (Loss) per Share Attributable to Common Shareholders:** Adjust net loss for various non-GAAP items and their tax impact to provide a more comparable measure of net profitability and a meaningful basis for forecasting future performance[29](index=29&type=chunk)[30](index=30&type=chunk)[31](index=31&type=chunk)[32](index=32&type=chunk)[33](index=33&type=chunk)[34](index=34&type=chunk)[35](index=35&type=chunk)[36](index=36&type=chunk) - These adjusted measures are **not alternatives to GAAP measurements** and may not be comparable to similarly titled measures reported by other companies[37](index=37&type=chunk) [Consolidated Financial Statements](index=6&type=section&id=Consolidated%20Financial%20Statements) Evolent Health's Q2 2025 consolidated financial statements show a significant net loss, decreased total assets with increased cash and long-term debt, and net cash used in operating activities [Consolidated Statements of Operations and Comprehensive Income (Loss)](index=6&type=section&id=Consolidated%20Statements%20of%20Operations%20and%20Comprehensive%20Income%20(Loss)) For the three months ended June 30, 2025, Evolent Health reported a net loss attributable to common shareholders of $(51.1) million, a substantial increase from $(6.4) million in the prior year, primarily due to decreased revenue and increased interest expense and dividends on Series A Preferred Stock Consolidated Statements of Operations (Q2 2025 vs Q2 2024) ($ in thousands) | Metric | Q2 2025 | Q2 2024 | Change | | :--------------------------------------------------- | :-------- | :-------- | :------- | | Revenue | $444,328 | $647,145 | -31.3% | | Total operating expenses | $445,499 | $639,357 | -30.3% | | Operating income (loss) | $(1,171) | $7,788 | -115.0% | | Net loss attributable to common shareholders | $(51,090) | $(6,383) | -700.4% | | Basic and diluted loss per common share | $(0.44) | $(0.06) | -633.3% | [Consolidated Balance Sheets](index=7&type=section&id=Consolidated%20Balance%20Sheets) As of June 30, 2025, Evolent Health's total assets decreased to $2.46 billion from $2.54 billion at December 31, 2024. Notable changes include an increase in cash and cash equivalents, a decrease in accounts receivable, and a significant increase in long-term debt Consolidated Balance Sheets (June 30, 2025 vs December 31, 2024) ($ in thousands) | Metric | June 30, 2025 | Dec 31, 2024 | Change | | :----------------------------------- | :-------------- | :------------- | :------- | | Total assets | $2,461,532 | $2,544,411 | -3.3% | | Cash and cash equivalents | $150,995 | $104,203 | +44.9% | | Accounts receivable, net | $358,756 | $414,681 | -13.5% | | Total current liabilities | $557,519 | $715,501 | -22.1% | | Long-term debt, net | $648,455 | $490,520 | +32.2% | | Total liabilities | $1,336,727 | $1,352,979 | -1.2% | | Total shareholders' equity | $896,005 | $1,001,259 | -10.5% | [Consolidated Statements of Cash Flows](index=8&type=section&id=Consolidated%20Statements%20of%20Cash%20Flows) For the six months ended June 30, 2025, Evolent Health reported net cash used in operating activities of $(25.8) million, a significant shift from cash provided in the prior year. Investing activities also used more cash, while financing activities provided a net cash inflow, leading to a slight net decrease in cash and restricted cash Consolidated Statements of Cash Flows (Six Months Ended June 30, 2025 vs 2024) ($ in thousands) | Metric | 2025 | 2024 | Change | | :--------------------------------------------------- | :--------- | :--------- | :------- | | Net cash and restricted cash (used in) provided by operating activities | $(25,769) | $26,326 | -197.9% | | Net cash and restricted cash used in investing activities | $(73,624) | $(23,273) | -216.3% | | Net cash and restricted cash provided by (used in) financing activities | $98,927 | $(88,499) | +211.7% | | Net (decrease) increase in cash and cash equivalents and restricted cash | $(526) | $(85,508) | +99.4% | | Cash and cash equivalents and restricted cash as of end-of-period | $177,970 | $137,949 | +29.0% | [Non-GAAP Reconciliations](index=13&type=section&id=Non-GAAP%20Reconciliations) This section provides detailed reconciliations of Evolent Health's GAAP to non-GAAP financial measures, including Adjusted Cost of Revenue, SG&A, EBITDA, and Adjusted Income (Loss) Attributable to Common Shareholders [Reconciliation of Adjusted Cost of Revenue](index=13&type=section&id=Reconciliation%20of%20Adjusted%20Cost%20of%20Revenue) For Q2 2025, Adjusted Cost of Revenue was $342.9 million, derived by subtracting $1.1 million in stock-based compensation from the GAAP Cost of Revenue of $343.9 million Reconciliation of Adjusted Cost of Revenue (Q2 2025 vs Q2 2024) ($ in thousands) | Metric | Q2 2025 | Q2 2024 | Change | | :-------------------------- | :-------- | :-------- | :------- | | Cost of revenue (GAAP) | $343,943 | $540,302 | -36.3% | | Less: Stock-based compensation | $1,050 | $1,207 | -13.0% | | Adjusted cost of revenue | $342,893 | $539,095 | -36.4% | [Reconciliation of Adjusted Selling, General and Administrative Expenses](index=13&type=section&id=Reconciliation%20of%20Adjusted%20Selling,%20General%20and%20Administrative%20Expenses) Adjusted Selling, General and Administrative Expenses for Q2 2025 totaled $63.9 million, after excluding $10.5 million in stock-based compensation, $0.8 million in severance costs, and other non-recurring items from the GAAP figure Reconciliation of Adjusted SG&A (Q2 2025 vs Q2 2024) ($ in thousands) | Metric | Q2 2025 | Q2 2024 | Change | | :--------------------------------------- | :-------- | :-------- | :------- | | Selling, general and administrative expenses (GAAP) | $75,209 | $69,185 | +8.7% | | Less: Stock-based compensation | $10,530 | $11,452 | -8.0% | | Less: Severance costs | $791 | $800 | -1.1% | | Less: Transaction-related costs | $0 | $163 | -100.0% | | Less: Repositioning costs | $0 | $670 | -100.0% | | Adjusted selling, general and administrative expenses | $63,888 | $56,100 | +13.9% | [Reconciliation of Adjusted EBITDA](index=14&type=section&id=Reconciliation%20of%20Adjusted%20EBITDA) Evolent's Adjusted EBITDA for Q2 2025 was $37.5 million, a decrease from $52.0 million in Q2 2024. This was calculated by adjusting the GAAP net loss attributable to common shareholders for various non-operating and non-cash items, including interest expense, depreciation and amortization, stock-based compensation, and dividends on Series A Preferred Stock Reconciliation of Adjusted EBITDA (Q2 2025 vs Q2 2024) ($ in thousands) | Metric | Q2 2025 | Q2 2024 | Change | | :--------------------------------------- | :-------- | :-------- | :------- | | Net loss attributable to common shareholders (GAAP) | $(51,090) | $(6,383) | -700.4% | | Interest expense | $11,601 | $5,995 | +93.5% | | Depreciation and amortization expenses | $23,141 | $29,870 | -22.6% | | Stock-based compensation expense | $11,580 | $12,659 | -8.5% | | Dividends and accretion of Series A Preferred Stock | $31,193 | $7,979 | +290.9% | | Adjusted EBITDA | $37,547 | $51,950 | -27.7% | | Adjusted EBITDA margin | 8.5% | 8.0% | +0.5 pp | [Reconciliation of Adjusted Income (Loss) Attributable to Common Shareholders](index=15&type=section&id=Reconciliation%20of%20Adjusted%20Income%20(Loss)%20Attributable%20to%20Common%20Shareholders) Evolent reported an Adjusted loss attributable to common shareholders of $(11.0) million for Q2 2025, a significant decline from an Adjusted income of $21.1 million in Q2 2024. This adjustment involved removing various non-GAAP items, including purchase accounting adjustments, stock-based compensation, and the tax impact of these adjustments Reconciliation of Adjusted Income (Loss) (Q2 2025 vs Q2 2024) ($ in thousands) | Metric | Q2 2025 | Q2 2024 | Change | | :--------------------------------------------------- | :-------- | :-------- | :------- | | Net loss attributable to common shareholders (GAAP) | $(51,090) | $(6,383) | -700.4% | | Purchase accounting adjustments | $13,364 | $17,189 | -22.2% | | Stock-based compensation expense | $11,580 | $12,659 | -8.5% | | Tax impact | $2,927 | $(5,600) | +152.3% | | Adjusted income (loss) attributable to common shareholders | $(11,013) | $21,065 | -152.3% | | Adjusted income (loss) per common share (Basic) | $(0.10) | $0.18 | -155.6% | [Forward-Looking Statements and Risk Factors](index=16&type=section&id=Forward-Looking%20Statements%20and%20Risk%20Factors) This section outlines cautionary language regarding forward-looking statements, detailing various risks and uncertainties that could materially impact Evolent Health's future performance [Forward-Looking Statements - Cautionary Language](index=16&type=section&id=Forward-Looking%20Statements%20-%20Cautionary%20Language) This section provides cautionary language regarding forward-looking statements, indicating that actual results may differ materially from expectations due to various risks and uncertainties. It outlines numerous factors that could impact future performance, including reliance on large partners, risk-sharing arrangements, ability to attract new partners, regulatory changes, data security, and the use of AI, advising investors not to place undue reliance on these statements - **Forward-looking statements** are predictions based on current expectations and projections about future events, subject to **risks and uncertainties** that may cause actual results to differ materially[47](index=47&type=chunk)[48](index=48&type=chunk) - **Significant portion of revenue derived from largest partners**, with potential for loss, termination, or renegotiation of contracts - **Increasing number of risk-sharing arrangements** and the ability to accurately predict exposure under performance-based contracts - **Ability to attract new partners** and offer new and innovative products and services, keeping pace with industry standards and technology - **Dependency on key personnel** and the ability to attract, hire, integrate, and retain them - **Risks related to completed and future acquisitions**, investments, alliances, and joint ventures, which could divert management resources or result in unanticipated costs - **Evolution of the healthcare regulatory and political framework**, restrictions on data access, and penalties from privacy and data protection laws - **Data loss or corruption due to system failures**, service disruptions, and liabilities related to safeguarding confidential data security and privacy - **Risks associated with the use of artificial intelligence (AI)** and machine learning models - **Ability to achieve profitability in the future** and the impact of additional goodwill and intangible asset impairments - **Indebtedness**, ability to service debt, and obtain additional financing on favorable terms - **Potential volatility of Class A common stock price** and provisions that discourage or prevent strategic transactions - **Impact of litigation proceedings**, government inquiries, public health emergencies, and increasing inflationary pressures[48](index=48&type=chunk)[51](index=51&type=chunk) - Investors should **not place undue reliance on forward-looking statements** as a prediction of actual results, and the company undertakes no obligation to publicly update them[50](index=50&type=chunk)